Neuronetics Launches Latest Evolution in its TrakStar® Patient Data Management System
12 Février 2024 - 2:32PM
Neuronetics, Inc. (NASDAQ: STIM), a medical technology company
focused on designing, developing, and marketing products that
improve the quality of life for patients who suffer from
neurohealth disorders, announced advancements to the TrakStar®
Patient Data Management System, a proprietary, HIPAA-compliant,
patient management and outcomes reporting system for providers
using NeuroStar TMS (transcranial magnetic stimulation). The update
introduces features to streamline the way practices track and
document status for their potential and current patients.
"It's essential for healthcare providers to have the most recent
technology that supports them in continuously improving patient
care processes," stated Cory Anderson, SVP of R&D and Clinical.
"These newest enhancements in TrakStar can facilitate better
internal practice communication and visibility to up-to-date and
comprehensive information about prospective and current NeuroStar
patients."
Included among the TrakStar developments are the ability to
identify and filter potential patients by the contact method that
led them to the practice, expanded methods for practices to update
potential patient status, and the capability to identify reasons
that existing and past patients ended treatment. All the features
are designed to save practices time, allowing them to focus more on
direct patient care rather than administrative tasks.
"My practice is here to provide our patients with the care and
respect they deserve during their mental wellness journey," said
Dr. Melissa Fickey, Founder of Embracing Life Wellness Center. "A
big part of that is being able to easily understand where they are
in the treatment process, and TrakStar helps us keep this
information visible and accessible at our fingertips."
Another notable feature in this TrakStar release is a more
robust Benefits Investigation report that provides practices with
estimated patient financial responsibility prior to a patient
beginning treatment. NeuroStar practices can now share this
information with patients during the consultation process and
provide immediate clarity in cost expectations from insurance
providers.
These TrakStar features are available now for all cloud-based
NeuroStar providers. For more information about NeuroStar TMS
Therapy, please visit NeuroStar.com.
About NeuroneticsNeuronetics,
Inc. believes that mental health is as important as physical
health. As a global leader in
neuroscience, Neuronetics is redefining patient and
physician expectations with its NeuroStar Advanced Therapy for
Mental Health. NeuroStar is a non-drug, noninvasive treatment that
can improve the quality of life for people suffering from
neurohealth conditions when traditional medication hasn’t helped.
In the United States, NeuroStar is FDA-cleared for adults with
major depressive disorder (MDD), as an adjunct for adults with
obsessive-compulsive disorder (OCD), and to decrease anxiety
symptoms in adult patients with MDD that may exhibit comorbid
anxiety symptoms (anxious depression). NeuroStar Advanced Therapy
is the leading transcranial magnetic stimulation (TMS) treatment
for MDD in adults with over 5.9 million treatments delivered.
NeuroStar is backed by the largest clinical data set of any TMS
system for depression, including the world’s largest depression
Outcomes Registry. Neuronetics is committed to
transforming lives by offering an exceptional treatment that
produces extraordinary results. For safety and prescribing
information, www.neurostar.com.
Media
Contact:EvolveMKD646.517.4220NeuroStar@evolvemkd.com
Neuronetics (NASDAQ:STIM)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Neuronetics (NASDAQ:STIM)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024